Related Experiment Video
Updated: May 29, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Bosentan for digital ulcers in patients with systemic sclerosis
Yayoi Nagai1, Michiko Hasegawa, Tomoyasu Hattori
1Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan. yanagai@showa.gunma-u.ac.jp
Bosutinib effectively treats digital ulcers in systemic sclerosis (SSc) patients, reducing pain and preventing new lesions. However, careful liver function monitoring is crucial due to potential side effects.
Area of Science:
- Vascular Medicine
- Rheumatology
- Dermatology
Background:
- Recurrent digital ulcers are a common and debilitating vascular complication in systemic sclerosis (SSc).
- Existing treatments often have limited efficacy for severe or refractory cases.
Purpose of the Study:
- To evaluate the efficacy and safety of bosentan in treating severe digital ulcers in patients with systemic sclerosis.
- To determine optimal dosing and identify potential adverse effects.
Main Methods:
- A case series of six patients with severe digital ulcers due to SSc treated with oral bosentan (62.5-125 mg daily).
- Observation periods ranged from 7 months to 4.5 years.
- Pain was assessed using a visual analog scale.
Main Results:
- Five of six patients experienced significant reduction in pain and cessation of new digital ulcer development.
- One patient had recurrence upon discontinuation but improved with re-administration.
- Three patients discontinued bosentan due to severe liver dysfunction.
Conclusions:
- Bosutinib appears effective for refractory digital ulcers in SSc, potentially at lower doses than used for pulmonary hypertension.
- Close monitoring of liver function is essential during bosentan treatment.
- Further research is warranted to confirm efficacy and optimize safety profiles.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Diabetic Foot Ulcer
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peripheral Artery Disease IV: Nursing Management

